Delving into the Latest Updates on Temoporfin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

2,3-dihydro-5,10,15,20-tetra(m-hydroxyphenyl)porphyrin, Foscan, Temoporfin (USAN/INN)

+ [8]

Target

Reactive oxygen species

Action

stimulants

Mechanism

Reactive oxygen species stimulants, Photosensitizers

Therapeutic Areas

Neoplasms

Active Indication

Squamous Cell Carcinoma of Head and Neck

Inactive Indication

Advanced Head and Neck CarcinomaCarcinoma bile duct non-resectable

Originator Organization

biolitec AG

Active Organization

biolitec Pharma Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

European Union (24 Oct 2001),

Squamous Cell Carcinoma of Head and Neck

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC44H32N4O4

InChIKeyLYPFDBRUNKHDGX-SOGSVHMOSA-N

CAS Registry122341-38-2

This phase I trial studies the side effects and best dose of photodynamic therapy during surgery in treating patients with non-small cell lung cancer that can be removed by surgery. Photodynamic therapy uses a drug, such as temoporfin, that becomes active when it is exposed to a certain kind of light. When the drug is active, cancer cells are killed. This may be a better way to treat patients with non-small cell lung cancer.

Start Date21 Feb 2014

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

NCT01718223

/ WithdrawnNot ApplicableIIT

A Pilot Study of Interstitial Photodynamic Therapy for Recurrent Squamous Cell Carcinoma of the Oropharynx and Oral Cavity

This pilot clinical trial studies photodynamic therapy using temoporfin before surgery in treating patients with recurrent oral cavity or oropharyngeal cancer. Photodynamic therapy uses a drug, such as temoporfin, that is absorbed by tumor cells. The drug becomes active when it is exposed to light. When the drug is active, tumor cells are killed. Giving photodynamic therapy using temoporfin before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Start Date01 Dec 2013

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

[+2]

100 Clinical Results associated with Temoporfin

Login to view more data

100 Translational Medicine associated with Temoporfin

Login to view more data

100 Patents (Medical) associated with Temoporfin

Login to view more data

794

Literatures (Medical) associated with Temoporfin

01 Jun 2025·Biomaterials

Two-photon photosensitizer for specific targeting and induction of tumor pyroptosis to elicit systemic immunity-boosting anti-tumor therapy

Article

Author: Xu, Dazhuang ; He, Yaohui ; Wang, Ziying ; Lu, Zhixiang ; Li, Man ; Liu, Gang ; An, Yibo ; Zeng, Yun ; Liu, Renyuan ; Tan, Yubo ; Tan, Xinyu ; Hu, Guosheng

Photodynamic therapy (PDT) has garnered increasing attention in cancer treatment due to its precise spatiotemporal selectivity and non-invasive nature. However, several challenges, including the inability of photosensitizers to discriminate between tumor and healthy tissues, as well as the limited tissue penetration depth of light sources, impede its broader application. To surmount these impediments, our research introduces a two-photon photosensitizer (TPSS) that specifically targets tumor overexpressing carbonic anhydrase IX (CA IX), thereby exhibiting exceptional specificity for tumor cells. Under two-photon laser stimulation, TPSS generates a large amount of reactive oxygen species (ROS), inducing cell pyroptosis and subsequently triggering a strong anti-tumor immune response. Additionally, proteomics analysis provides compelling evidence to elucidate the anti-tumor mechanism of TPSS in vivo. Through comprehensive immune assessments, TPSS under two-photon laser irradiation effectively activates both the innate and adaptive immune systems, efficiently suppressing the proliferation of distant metastatic tumors, underscoring its considerable therapeutic potential. Collectively, this study provides a viable strategy to overcome the limitations of PDT, highlighting the prospects of two-photon excitation photosensitizers.

01 Apr 2025·Photodiagnosis and Photodynamic Therapy

Efficacy of canal disinfectants Temoporfin, carbon nanoparticles, and Er: YAG laser on martens hardness, smear layer removal, and bond strength of glass fiber posts to canal dentin

Article

Author: Alsahhaf, Abdulaziz

AIMTo investigate the effectiveness of unconventional post space disinfection techniques, specifically Er:YAG laser, Temoporfin, and Carbon Nanoparticles (CNPs), in improving Martens hardness (MH), eliminating the smear layer (SL), and enhancing the push-out bond strength (PBS) of glass fiber posts in canal dentin.METHODSAn in vitro study was conducted utilizing 80 single-rooted extracted human teeth, which were decoronated and subjected to standardized root canal preparation. The teeth were equally distributed into four experimental groups: Group 1 (NaOCl + EDTA), Group 2 (Er: YAG laser + EDTA), Group 3 (Temoporfin + EDTA), and Group 4 (CNPs + EDTA). Each group underwent disinfection protocols followed by assessment of Martens hardness (MH) using nanoindentation testing, SL evaluation via scanning electron microscopy, and bond strength testing using a universal testing machine (UTM). Statistical analysis was performed using one-way ANOVA followed by Tukey's post hoc test to determine the level of significance among the groups. A significant level of p<0.05 was established.RESULTSGroup 4 (CNPs+17% EDTA) showed a high MH value of (0.25 ± 0.02 GPa), significantly outperforming Groups 1 (0.13 ± 0.02 GPa) and 3 (0.10 ± 0.03 GPa). Group 2 (Er: YAG laser + 17% EDTA) demonstrated superior smear layer removal across all sections, particularly in the apical third (1.94 ± 0.38). Push-out bond strength was highest in Group 2 (9.98 ± 0.14 MPa at the cervical level) and Group 4 (10.08 ± 0.21 MPa), while Group 1 showed a decrease in apical bond strength of (5.11 ± 0.19 MPa) CONCLUSION: CNPs and Er:YAG laser treatments, in comparison to Temoporfin and NaOCl, significantly increase dentin hardness and bond strength while reducing SL. This finding suggests that the incorporation of these innovative disinfection methods into endodontic procedures may enhance the durability and success of glass fiber post restorations.

23 Jan 2025·Mikrobiyoloji Bulteni

Temoporfin Aracılı Fotodinamik İnaktivasyonun Leishmania tropica Promastigotları Üzerindeki Etkileri ve Moleküler Yerleştirme Analizi

Article

Author: Özlem Çalişkan, Serçin ; Ertabaklar, Hatice ; Şimşek, Hilal ; Aytar, Erdi Can ; Çalişkan, Metin

Layşmanyaz, yaklaşık 90'dan fazla ülke ve bölgeden bildirilen, ciddi ve endemik bir bulaşıcı hastalıktır. Kutanöz layşmanyaz (KL) ise vücudun açıkta kalan bölgelerinde oluşan, başlıca semptomları arasında vektör Phlebotomus ısırığından altı ay sonra kronikleşebilen veya kendiliğinden iyileşebilen ciltte tek, birden fazla ülserli veya nodüler lezyonlar bulunan, ölümcül olmayan ancak kalıcı izler bırakabilen bir hastalıktır. Klasik tedavi yöntemleri, uygulamada zorluk, direnç gelişimi ve yan etki gibi bir dizi soruna neden olmaktadır. Fotodinamik tedavi (FDT), KL tedavisi için etkili, uygulaması kolay ve invaziv olmayan büyük bir potansiyel göstermektedir. Antilayşmanyal tedavi için yeni modalitelerden olan FDT, ışık ve fotosensitizerin eş zamanlı kombinasyonuyla antilayşmanyal etkileri artırmayı hedeflemektedir. Bu çalışmada, FDT'nin antilayşmanyal etkisinin incelenmesi hedefine yönelik olarak temoporfin aracılı fotodinamik inaktivasyonun Leishmania tropica promastigotları üzerindeki antilayşmanyal etkisinin ve olası mekanizmalarının in vitro olarak gösterilmesi amaçlanmıştır. Parazitler 0.5, 1, 2, 4, 8 ve 16 μM temoporfin ile 50 dakika süreyle inkübe edilmiş ve 50 dakikalık 1.71 J/cm²'lik bir akıyla kırmızı ışığa maruz bırakılmıştır. Hücre canlılığının değerlendirilmesi için MTT testi kullanılmış ve morfolojik değişiklikler Giemsa boyama yöntemiyle analiz edilmiştir. L.tropica promastigotlarında aşırı ifade edilen reseptörlere en yüksek bağlanma afinitesini bulmak için ise moleküler yerleştirme yöntemi kullanılmıştır. Temoporfin ve kırmızı ışık kombinasyonu ile L.tropica promastigot canlılığının sadece temoporfin grubuna göre anlamlı derecede azaldığı bulunmuştur. Temoporfin ve kırmızı ışık kombinasyonu sonucunda gözlenen IC50 değeri L.tropica için 1.924 μM olarak tespit edilmiştir. 1.924 μM konsantrasyonda sadece temoporfin ve sadece kırmızı ışık uygulamasının L.tropica promastigotları üzerinde anlamlı bir etkisinin olmadığı gözlemlenmiştir. Ayrıca temoporfin aracılı kırmızı ışık grubunda fusiform şeklin değişmesi, kamçı ve çekirdek kaybı gibi tipik morfolojik özelliklerin kaybolduğu da tespit edilmiştir. Moleküler yerleştirme yöntemine göre ise amfoterisin B ve temoporfin 5WB5 proteininin üç boyutlu modeline sırasıyla -7.4 kcal/mol ve -6.9 kcal/mol bağlanma afinitesi göstermiştir. Temoporfin ile kırmızı ışık kombinasyonu, L.tropica promastigotlarını invaziv olmayan bir tedavi olarak inaktive etme potansiyeline sahiptir. Tedavide kullanılan FDT bileşenleri olan kırmızı ışık ve temoporfinin herhangi bir sitotoksik etkisinin bulunmaması, amastigot veya hayvan modelleri üzerine yapılacak daha ileri çalışmalar için önemli bir fırsat sunmakta ve potansiyel klinik uygulamalara zemin hazırlamaktadır.

100 Deals associated with Temoporfin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D06066	Temoporfin	L01XD05	DB11630

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Squamous Cell Carcinoma of Head and Neck	Liechtenstein	biolitec Pharma Ltd.	24 Oct 2001
Squamous Cell Carcinoma of Head and Neck	Iceland	biolitec Pharma Ltd.	24 Oct 2001
Squamous Cell Carcinoma of Head and Neck	Norway	biolitec Pharma Ltd.	24 Oct 2001
Squamous Cell Carcinoma of Head and Neck	European Union	biolitec Pharma Ltd.	24 Oct 2001

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Head and Neck Carcinoma	Phase 2	United States	biolitec Pharma Ltd.	01 Nov 2010
Squamous Cell Carcinoma of Head and Neck	Phase 2	United States	biolitec Pharma Ltd.	01 Nov 2010
Carcinoma bile duct non-resectable	Phase 2	Austria	biolitec Pharma Ltd.	01 Jan 2006
Carcinoma bile duct non-resectable	Phase 2	Germany	biolitec Pharma Ltd.	01 Jan 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01016002 (not available, UEGW2014)	Phase 2	-	-	Temoporfin PDT	lxcezwwbrv(ngrkhdcsno) = bsvveluywc zhhtyelylv (ihgnenspzc ) View more	Positive	01 Oct 2014
NCT01016002 (not available, UEGW2014)	Phase 2	-	-	Porfimer PDT	(doxwpgyojn) = eixonzhzop aoseapohij (jtmtpuuxih, 11.7 - 19.1)	Positive	01 Oct 2014
NCT01016002 (Pubmed \| Photochem Photobiol Sci)	Phase 2	Bile Duct Neoplasms	-	Temoporfin PDT	hkgovrxbhr(hisbmchuwn) = tllqdxdvbr zwfeziorqr (okfhnrryko, 4.4 - 32.0) View more	-	01 Jun 2013
TEM-HNC-001 (ASCO2008)	Not Applicable	Advanced Head and Neck Squamous Cell Carcinoma	39	Temoporfin-mediated photodynamic therapy	bbwdgpwkpg(tgubetykbl) = 21% of patients izdustkdto (qrpszxfslh ) View more	-	20 May 2008